0001628280-24-025886.txt : 20240530 0001628280-24-025886.hdr.sgml : 20240530 20240530174125 ACCESSION NUMBER: 0001628280-24-025886 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240528 FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bonstein Sara CENTRAL INDEX KEY: 0001604019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 241006884 MAIL ADDRESS: STREET 1: 305 COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 4 1 wk-form4_1717105276.xml FORM 4 X0508 4 2024-05-28 0 0001104506 INSMED Inc INSM 0001604019 Bonstein Sara 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 0 1 0 0 Chief Financial Officer 1 Common Stock 2024-05-28 4 M 0 3454 28.88 A 120935 D Common Stock 2024-05-29 4 M 0 76731 28.88 A 197666 D Common Stock 2024-05-28 4 M 0 3454 24.70 A 201120 D Common Stock 2024-05-29 4 M 0 27074 24.70 A 228194 D Common Stock 2024-05-28 4 M 0 3454 34.03 A 231648 D Common Stock 2024-05-29 4 M 0 25046 34.03 A 256694 D Common Stock 2024-05-28 4 M 0 3454 26.46 A 260148 D Common Stock 2024-05-29 4 M 0 39446 26.46 A 299594 D Common Stock 2024-05-28 4 M 0 3454 26.43 A 303048 D Common Stock 2024-05-29 4 M 0 20111 26.43 A 323159 D Common Stock 2024-05-28 4 M 0 3454 17.07 A 326613 D Common Stock 2024-05-29 4 M 0 32156 17.07 A 358769 D Common Stock 2024-05-28 4 S 0 20724 50.01 D 338045 D Common Stock 2024-05-29 4 S 0 220564 50 D 117481 D Stock Option (right to buy) 28.88 2024-05-28 4 M 0 3454 0 D 2030-02-03 Common Stock 3454 88186 D Stock Option (right to buy) 28.88 2024-05-29 4 M 0 76731 0 D 2030-02-03 Common Stock 76731 11455 D Stock Option (right to buy) 24.70 2024-05-28 4 M 0 3454 0 D 2030-05-12 Common Stock 3454 31436 D Stock Option (right to buy) 24.70 2024-05-29 4 M 0 27074 0 D 2030-05-12 Common Stock 27074 4362 D Stock Option (right to buy) 34.03 2024-05-28 4 M 0 3454 0 D 2031-01-07 Common Stock 3454 42146 D Stock Option (right to buy) 34.03 2024-05-29 4 M 0 25046 0 D 2031-01-07 Common Stock 25046 17100 D Stock Option (right to buy) 26.46 2024-05-28 4 M 0 3454 0 D 2031-05-12 Common Stock 3454 65186 D Stock Option (right to buy) 26.46 2024-05-29 4 M 0 39446 0 D 2031-05-12 Common Stock 39446 25740 D Stock Option (right to buy) 26.43 2024-05-28 4 M 0 3454 0 D 2032-01-06 Common Stock 3454 59386 D Stock Option (right to buy) 26.43 2024-05-29 4 M 0 20111 0 D 2032-01-06 Common Stock 20111 39275 D Stock Option (right to buy) 17.07 2024-05-28 4 M 0 3454 0 D 2032-05-11 Common Stock 3454 91506 D Stock Option (right to buy) 17.07 2024-05-29 4 M 0 32156 0 D 2032-05-11 Common Stock 32156 59350 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 20,724 shares sold at prices ranging from $50.00 to $50.07 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 220,564 shares sold at prices ranging from $50.00 to $50.08 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. The options are exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein's continued employment with the Company on each vesting date. /s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact 2024-05-30